Profil
Paul Rivard is currently the VP-Operations & General Counsel at MyMD Pharmaceuticals (Florida), Inc. Previously, he held the position of President & General Counsel at MIRA Pharmaceuticals, Inc. He also served as the Chief Legal Officer & Vice President-Operations at TNF Pharmaceuticals, Inc. from 2021 to 2023.
Mr. Rivard completed his undergraduate degree at Clarkson University in 1992 and obtained his graduate degree from Columbus School of Law in 1998.
Postes actifs de Paul Rivard
| Sociétés | Poste | Début |
|---|---|---|
MyMD Pharmaceuticals (Florida), Inc.
MyMD Pharmaceuticals (Florida), Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage pharmaceutical company that develops therapeutic platforms | Directeur des opérations | - |
Anciens postes connus de Paul Rivard
| Sociétés | Poste | Fin |
|---|---|---|
| Q/C TECHNOLOGIES, INC. | Directeur des opérations | 14/11/2023 |
| MIRA PHARMACEUTICALS, INC. | President | - |
Formation de Paul Rivard
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Clarkson University
Clarkson University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Columbus School of Law
Columbus School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MyMD Pharmaceuticals (Florida), Inc.
MyMD Pharmaceuticals (Florida), Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage pharmaceutical company that develops therapeutic platforms | Health Technology |
MyMD Pharmaceuticals, Inc.
MyMD Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage pharmaceutical company that engages in the development of drug products to extend healthy lifespan | Health Technology |
MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. Pharmaceuticals: OtherHealth Technology Develops and sells new molecular synthetic THC for the treatment of adult patients with anxiety and cognitive decline | Health Technology |
















